Loader

Pathways

PathWhiz ID Pathway Meta Data

PW123617

Pw123617 View Pathway
signaling

Ярослав

Arabidopsis thaliana

PW147028

Pw147028 View Pathway
metabolic

γ-Aminobutyric acid Drug Metabolism Pathway

Homo sapiens

PW146981

Pw146981 View Pathway
metabolic

βzole Drug Metabolism Pathway

Homo sapiens

PW147040

Pw147040 View Pathway
metabolic

βhistine Drug Metabolism Pathway

Homo sapiens

PW146977

Pw146977 View Pathway
metabolic

α-Tocopherol Drug Metabolism Pathway

Homo sapiens

PW147035

Pw147035 View Pathway
metabolic

α-Lactose Drug Metabolism Pathway

Homo sapiens

PW146448

Pw146448 View Pathway
drug action

Zytron Drug Metabolism Action Pathway

Homo sapiens

PW132411

Pw132411 View Pathway
metabolic

Zytron Drug Metabolism

Homo sapiens
Zytron is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Zytron passes through the liver and is then excreted from the body mainly through the kidney.

PW176840

Pw176840 View Pathway
drug action

Zuclopenthixol H1-Antihistamine Immune Response Action Pathway

Homo sapiens
Zuclopenthixol is a weak H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.

PW176748

Pw176748 View Pathway
drug action

Zuclopenthixol H1-Antihistamine Blood Vessel Constriction Action Pathway

Homo sapiens
Zuclopenthixol is a weak H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. H1-antihistamines act on H1 receptors in T-cells to inhibit the immune response, in blood vessels to constrict dilated blood vessels, and in smooth muscles of lungs and intestines to relax those muscles. Allergies causes blood vessel dilation which causes swelling (edema) and fluid leakage. Zuclopenthixol inhibits the H1 histamine receptor on blood vessel endothelial cells. This normally activates the Gq signalling cascade which activates phospholipase C which catalyzes the production of Inositol 1,4,5-trisphosphate (IP3) and Diacylglycerol (DAG). Because of the inhibition, IP3 doesn't activate the release of calcium from the sarcoplasmic reticulum, and DAG doesn't activate the release of calcium into the cytosol of the endothelial cell. This causes a low concentration of calcium in the cytosol, and it, therefore, cannot bind to calmodulin. Calcium bound calmodulin is required for the activation of the calmodulin-binding domain of nitric oxide synthase. The inhibition of nitric oxide synthesis prevents the activation of myosin light chain phosphatase. This causes an accumulation of myosin light chain-phosphate which causes the muscle to contract and the blood vessel to constrict, decreasing the swelling and fluid leakage from the blood vessels caused by allergens.